Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, in a deal designed to expand the buyer’s rare immunological disease portfolio with an FDA-approved ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

Here are some of the stocks on the move on Monday, June 2. Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) agreed to acquire the company for up to $9.5 billion. Boeing (BA) shares ...

Sanofi SAN-1.02 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...